Abstract
Abnormalities in the tumor suppressor TP53 are among the most common mechanisms of cancer pathogenesis (Lane and Levine 2010) and formed the rationale for TP53 gene therapy to restore normal p53 function in cancer treatment. Several important principles were elucidated in preclinical tumor models which predicted the outcomes of subsequent clinical trials including synergistic antitumor activity for combined TP53 gene therapy plus DNA damaging chemotherapy and radiation (Zhang and Roth 1994; Gjerset and Sobol 1997; Nielsen and Maneval 1998).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R (2006) Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer Gene Ther 13(2):169–181
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA et al (1996) An adenovirus mutant that replicates selectively in p53- deficient human tumor cells. Science 274(5286):373–376
Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H (1998) Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16(6):2221–2232
Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ (1995) Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14(4):275–285
Gjerset RA, Sobol RE (1997) Treatment resistance, apoptosis and p53 tumor suppressor gene therapy. In: Bertino J (ed) Encyclopedia of Cancer. Academic Press, Waltham, Massachusetts pp 1785–1791
Guan YS, Liu Y, Zou Q, He Q, La Z, Yang L, Hu Y (2009) Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up. J Zhejiang Univ Sci B 10(5):331–340
Guan YS, Liu Y, He Q, Li X, Yang L, Hu Y, La Z (2011) p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up. World J Gastroenterol 17(16):2143–2149
Khuri F, Nemunaitis J, Ganly I, Arseneau J, Tannock I, Romel L, Gore M, Ironside J et al (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med 6(8):879–885
Lane D, Levine A (2010) p53 research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2(12):a000893
Li LJ, Ding HY, Wang LJ, Ming WY, Han B (2006) A combination therapy of selective intraarterial adenoviral p53 infusion with chemotherapy for locally advanced head and neck carcinoma: a prospective clinical phase II study. Molecular Ther, Volume 13, Supplement 1, May
Li Y, Li LJ, Zhang ST, Wang LJ, Zhang Z, Gao N, Zhang YY, Chen QM (2009) In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin Cancer Res 15(21):6724–6731
Lippman SM (1997) Head and neck chemoprevention: recent advances. Cancer Control 4(2):128–135
Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233–1238
Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, Hamm J, Yoo G, Baselga J, Murphy BA, Menander KA, Licato LL, Chada S, Gibbons RD, Olivier M, Hainaut P, Roth JA, Sobol RE, Goodwin WJ (2009) Biomarkers predict p53 gene therapy efficacy in recurrent squamous cell carcinoma of the head and neck. Clin Cancer Res 15(24):7719–7725
Nielsen LL, Maneval DC (1998) P53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 5:52–63
Nishizaki M, Fujiwara T et al (1999) Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 5:1015–1023
Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA, Ji L (2001) Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 7(9):2887–2897
Peng Z (2005) Current status of Gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16(9):1016–1027
Reid T, Warren R, Kirn D (2002) Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 9(12):979–986
Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2(9):985–991
Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, Gabra H, Eeles R, Sodha N, Lynch FJ, Zumstein LA, Menander KB, Sobol RE, Chada S (2007) p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther 6(5):1478–1482
Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M (2003) Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93–101
Tolcher AW, Hao D, de Bono J, Miller A, Patnaik A, Hammond LA, Smetzer L, Van Wart HJ, Merritt J, Rowinsky EK, Takimoto C, Von Hoff D, Eckhardt SG (2006) Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol 24(13):2052–2058
Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT et al (1994) Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5(9):1079–1088
Xue W, Zender L et al (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445(7128):656–660
Yu W, Fang H (2007) Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 7(2):141–8
Zambetti G, Levine A (1993) A comparison of the biological activities of wild-type and mutant p53. FASEB J 7:855–865
Zhang WW, Fang X, Mazur W, French BA, Georges RN, Roth JA (1994) High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1(1):5–13
Zhang WW, Roth JA (1994) Anti-oncogene and tumor suppressor gene therapy–examples from a lung cancer animal model. Vivo 8(5):755–69
Acknowledgments
This manuscript is dedicated with deep appreciation and gratitude to Eleanor McGlaughlin who exemplifies the finest qualities of an inspirational teacher—the source of all achievements.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Conflict of Interest
The following authors have or had employment/advisor (E/A) or investigator (I) relationships with the companies developing Advexin (p53 Inc/Introgen), Gendicine (SiBiono) and SCH58500 (Schering-Plough/Merck):
p53 Inc: Robert E. Sobol(E/A); Wei-Wei Zhang(E/A); Kerstin B. Menander(E/A); Sunil Chada(E/A); Daniel C. Maneval (E/A); Gary L. Clayman(I); Stephen G. Swisher(I); W. Jarrard Goodman(I); John Nemunaitis(I); Jack A. Roth(I/E/A)
SiBiono: Zhaohui Peng(E/A); Wei-Wei Zhang(E/A); Yong-Song Guan(I); Long-Jiang Li(I)
Schering-Plough/Merck: Daniel C. Maneval(E/A); Jane A. Horowitz(E/A); Robert Warren(I)
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sobol, R.E. et al. (2013). Tp53 Gene Therapy for Cancer Treatment and Prevention. In: Hainaut, P., Olivier, M., Wiman, K. (eds) p53 in the Clinics. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3676-8_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3676-8_11
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3675-1
Online ISBN: 978-1-4614-3676-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)